Update: Value of c-Met inhibitor in NSCLC questioned
Detailed data presented at ASCO 2014 on c-Met inhibitors, including Roche's onartuzumab and ArQule's tivantinib, failed to show much clinical benefit when a c-Met inhibitor is added to other therapies in NSCLC, and posed the question of whether inhibiting c-Met in this disease setting is clinically meaningful. This, however, should not have reduced tivantinib's value in HCC, in which two Phase III trials, METIV-HCC and JET-HCC, are progressing in second-line HCC. ArQule ended Q114 with cash and marketable securities of $85.8m, enough to support its operation beyond 2015.ArQule is a biopharmaceutical company engaged in the research and development of therapeutics to treat cancers and rare diseases. The company's clinical pipeline includes: ARQ 531, which is a reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase for B-cell malignancies refractory to other therapeutic options; Miransertib, which is a selective inhibitor of protein kinase B (AKT) in combination with the hormonal therapy, anastrozole; ARQ 751, which is a selective inhibitor of AKT for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase and tensin homolog (PTEN) mutations or that are PTEN null; and Derazantinib, which is a multi-kinase inhibitor.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.